| Zejula (niraparib) / GSK, J&J |
ChiCTR2200064890: Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib |
|
|
| Not yet recruiting | N/A | 67 | | Avatrombopag | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self selected topic: Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib(SKX-CIT-2210) | Thrombocytopenia in patients with ovarian cancer | | | | |
NCT04589039: A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Ovarian Neoplasms | 12/24 | 12/24 | | |
CONOR, NCT05857397: A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America |
|
|
| Recruiting | N/A | 96 | RoW | Observational study | Latin American Cooperative Oncology Group, GlaxoSmithKline | Ovarian Cancer | 04/25 | 04/25 | | |
NCT05021562: A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice |
|
|
| Recruiting | N/A | 300 | Japan | Niraparib | Takeda | Ovarian Cancer | 03/26 | 03/26 | | |
ChiCTR2300068357: A multicenter clinical trial study of the PARP inhibitor niraparib combined with radiation therapy in the treatment of children with H3K27M mutation diffuse intrinsic pontine glioma (DIPG) |
|
|
| Recruiting | N/A | 40 | | None Treatment ;Radiation therapy (60 Gy) ;Radiation therapy (60 Gy) + Niraparib (100 mg/d) | The Third Affiliated Hospital of Zhengzhou University; The Third Affiliated Hospital of Zhengzhou University, The Third Affiliated Hospital of Zhengzhou University | Pediatric diffuse intrinsic pontine gliomas | | | | |
RENI-1, NCT04986371: Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer |
|
|
| Not yet recruiting | N/A | 300 | NA | Niraparib, Zejula | Ling-Ying Wu | Epithelial Ovarian Cancer | 08/22 | 02/25 | | |
| Not yet recruiting | N/A | 100 | RoW | PARP inhibitor, Lynparza, Zejula | Xiaoxiang Chen | Ovarian Cancer, HRD, PARP Inhibitor | 09/22 | 09/23 | | |
NCT05583799: Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. |
|
|
| Not yet recruiting | N/A | 222 | NA | | First Affiliated Hospital Xi'an Jiaotong University | Ovarian Cancer | 05/25 | 09/25 | | |